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1. Introduction 
The incidence of female breast cancer has increased 0.5% since the year 2000, as reported by 
the International Agency Research on Cancer. This number is greater in developing 
countries due to the increase in life expectancy and change in behavior resulting in 
increased exposure to risk factors. 
Lymph node staging is an early event carried out during initial patient evaluation in 
developed countries. Some 20% to 30% of all cases are diagnosed quite early (in situ lesions) 
DCIS; 79% of the patients diagnosed at stage I and II has negative axillary nodes; (Holland 
et al., 2001). These values are somewhat different in developing countries where more than 
50% of the cases are diagnosed at advanced stages of the disease.  
Increased survival rates have been reported lately. According to Parkin (Parkin et al., 2001), 
the overall survival rate is 91% after the first year and 65% after five years in Europe. These 
values increase to 96.8% after the first year in the United States. As primary prevention of 
breast cancer is not available as yet, early detection and treatment in the initial phase of the 
disease are, therefore, the most important measures for its control (INCA, 2009). Available 
diagnostic methods include mammography, breast ultrasonography and fine-needle 
aspiration biopsy among others (Moore et al., 1996; Morton et al., 1998).  
Until 1990, the assessment of axillary status of a patient with breast cancer depended on the 
histopathologic examination of lymph nodes from complete axillary dissection. With the 
definition of the sentinel lymph node as the first one which receives the drainage of the 
tumoral area (Cabanas, 1977), it was possible to ensure means for the proper staging of the 
illness and the therapeutic approach establishing less invasive surgery techniques.  
Currently, it is admitted that the presence of metastatic lymph nodes is the main predictor 
factor for prognosis of the breast malignant neoplasia course and subsequent therapeutic 
program. Lymph nodes are also valuable for staging breast cancer. In the recent past 
dissection of the axillary lymph nodes was required for this matter, resulting in a series of 
additional complications (Veronesi et al., 1999). 
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2. Sentinel lymph node biopsy on breast cancer surgery 
The status of the axillary lymph nodes is one of the most important prognostic factors in 
women with early stage breast cancer. Histologic examination of lymph nodes is the most 
accurate method for assessing spread of disease to these nodes. 
Axillary lymph node dissection (ALND) has traditionally been a routine component of the 
management of early breast cancer. The benefits of ALND include its impact on disease 
control (ie, axillary recurrence and survival), its prognostic value, and its role in treatment 
selection. However, the anatomic disruption caused by ALND may result in lymphedema, 
nerve injury, and shoulder dysfunction, which compromise functionality and quality of life. 
ALND remains the standard approach for women who have clinically palpable axillary 
nodes or positive nodes confirmed by methods such as ultrasound guided fine needle 
aspiration. For patients who have clinically negative axillary lymph nodes, sentinel lymph 
node biopsy (SLNB) is a less morbid method of staging the axilla than ALND.  
Indications for and outcomes of SLNB will be reviewed here.  
The sentinel lymph node (SLN) technique is based upon the observation that tumor cells 
migrating from a primary tumor metastasize to one or a few lymph nodes (LNs) before 
involving other LNs. Injection of vital blue dye and/or radiolabeled colloid around the area 
of the tumor permits identification of a SLN in the majority of patients, and its status 
accurately predicts the status of the remaining regional LNs. 
In patients with clinically node negative breast cancer, SLNB identifies patients without 
axillary node involvement, thereby obviating the need for more extensive surgery. Several 
studies have shown that the risk of arm morbidity, particularly lymphedema, sensory loss, 
and shoulder abduction deficits, is significantly less for SLNB than with standard axillary 
dissection. As an example, the risk of lymphedema after 12 months was reported as 2 
percent after SLNB alone as compared with 13 percent after SLNB with axillary lymph node 
dissection (ALND) in the American College of Surgeons Oncology Group (ACOSOG) Z-
0011 trial.  
Most surgeons and major cancer centers have adopted SLNB as a standard means of axillary 
nodal assessment. In a study of over 490,000 women with early breast cancer from the 
National Cancer Database, use of SLNB increased from 27 to 66 percent between 1998 and 
2005 in the United States. Similar trends have been reported from Canada and the United 
Kingdom. SLNB is endorsed as an alternative to ALND for the diagnosis of axillary 
metastases in patients with clinically node-negative early breast cancer in guidelines from 
the American Society of Clinical Oncology (ASCO), the International Expert Consensus 
Panel on the Primary Therapy of Early Breast Cancer, and others. 
Despite variability in selection criteria and technique, a SLN is consistently identified in 
approximately 96 percent of cases, and predicts the status of the remaining axillary LNs in 
≥95 percent of cases in most series. The false negative rate of SLNB was originally reported 
as 5 to 10 percent (sensitivity 90 to 95 percent), but lower rates are attainable by experienced 
surgeons. 
The greatest concern with SLNB is the potential of a false negative result, which could 
increase the potential for axillary recurrence. However, despite the approximately 5 to 10 
percent false negative rate with SLNB found in studies in which completion ALND has been 
done, several series suggest that axillary recurrence rates are low after a negative SLNB 
alone in early stage breast cancer (range 0 to 4.5 percent). The details of key trials validating 
the SLNB are described below: 
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A landmark multicenter study of 443 patients with early breast cancer demonstrated that the 
SLNB technique could be learned and successfully applied by a diverse group of surgeons 
spanning private and academic practice. All patients underwent SLNB using radiolabeled 
colloid followed by completion ALND. At least one SLN was identified in 98 percent of 
cases and the predictive value of a negative SLN was 96 percent, with a false negative rate of 
11 percent (sensitivity 88 percent). More intensive pathologic evaluation of the nodes in false 
negative cases with deeper sectioning of the sentinel node and immunohistochemical 
staining increased the yield of occult metastases in 18 percent of cases. 
A systematic review, performed by the ASCO expert guidelines panel, included 69 eligible 
trials of SLNB in early stage breast cancer, representing 8059 patients. The SLN was 
identified using radiocolloid, blue dye, or both. SLN identification was successful in 95 
percent of patients. The false negative rate was 7.3 percent (range 0 to 29 percent). The 
combination of radiocolloid and blue dye resulted in a significantly higher success rate in 
SLN mapping with a lower false negative rate as compared to blue dye alone. 
The NSABP B-32 trial, published after the systematic review, enrolled 5611 patients with 
clinically negative nodes and compared SLNB followed by ALND versus SLNB followed by 
ALND only if the SLN was positive. Lymphatic mapping was successful in 97 percent, and 
the false-negative rate was 9.8 percent. No significant differences were observed in regional 
control, overall survival, or disease free survival between the groups at a median follow-up 
of almost eight years.  
SLNB should be performed in most women with clinically node negative invasive or 
microinvasive breast cancer. SLNB can be omitted if the nodal information will not affect 
adjuvant treatment decisions. As an example, women ≥70 years of age who have a small (<2 
cm) estrogen receptor-positive tumor and a clinically uninvolved axilla may be treated 
without a SLNB. Although older patients do not appear to be at increased risk of 
complications following axillary clearance, retrospective analyses and one randomised trial 
have questioned its value in older women with breast cancer (IBCSG, 1996). In a randomised 
trial, 473 women aged 60 or over. Interestingly in the ALMANAC trial (comparing sentinel 
node biopsy and standard axillary treatment), which used validated measures of patient 
reported quality of life and arm morbidity, older women (65 years and over) irrespective of 
axillary management had better quality of life outcomes at all stages of the 18-month follow-
up than younger women (Fleissig et al, 2006). 
SLNB should be performed in women with extensive ductal carcinoma in situ (DCIS), who 
are undergoing mastectomy. A SLNB will not be possible after mastectomy if invasive 
disease is found on final pathology, necessitating an axillary dissection for staging purposes. 
(See 'Ductal carcinoma in situ' below.) 
When a SLNB is not successful or when clinically suspicious nodes are present in the axilla 
after all sentinel lymph nodes have been removed, the surgeon should perform an axillary 
dissection for staging purposes and to ensure locoregional control.  
For women with clinically suspicious lymph nodes, preoperative axillary ultrasound (US) 
with fine needle aspiration (FNA) or core biopsy of suspicious areas provides a means to 
identify patients who have positive nodes, and thus need axillary lymph node dissection 
(ALND) rather than a SLNB. As an example, in a series of 653 consecutive patients, the 
preoperative diagnosis rate of axillary disease was 23 percent using axillary US and FNA, 
thereby avoiding the need for a second operation in 150 women. The efficacy of this 
approach is somewhat variable between centers because the accuracy of US examination is 
operator dependent. 
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Approximately 40 percent of patients with a positive sentinel lymph node (SLN) will be 
found to have residual disease in the axilla SLN metastases are categorized as isolated 
tumor cells, micrometastases or macrometastases, depending on the size of the largest 
tumor deposit in the SN. Treatment options will depend on the clinical situation and include 
completion axillary lymph node dissection (ALND) or axillary radiation therapy (RT).  
Isolated tumor cells — The seventh edition of the American Joint Committee on Cancer 
(AJCC) tumor node metastasis (TNM) staging system for breast cancer includes a stringent 
classification for lymph node findings of isolated tumor cell clusters and single cells. Small 
clusters of cells not greater than 0.2 mm, or nonconfluent or nearly confluent clusters of cells 
not exceeding 200 cells in a single histologic lymph node cross section are classified as 
isolated tumor cells and are considered node negative. Malignant cells in regional lymph 
node(s) no greater than 0.2 mm (detected by H&E or IHC including ITC) are designated as 
pN0(i+). Isolated tumor cells are not considered an indication for further axillary surgery, 
radiation treatment or adjuvant systemic therapy. 
SLNB allows the pathologist to perform a more detailed study of one or a few LNs that are 
most likely to contain metastases, compared to the 15 to 25 LNs obtained with ALND. This 
has the potential to improve staging accuracy, but has led to an increase in the identification 
of micrometastatic nodal involvement. For this reason, there is a separate designation of 
pN1mi (>0.2 mm and no greater than 2.0 mm) to indicate micrometastases alone. 
Although it seems intuitive that the finding of axillary micrometastases should worsen 
prognosis, most studies show no reduction in patient survival compared to those without 
micrometastases. However, some analyses do suggest a negative impact of micrometastases 
on breast cancer outcomes.  
There is debate about the prognostic value of the size of the SLN micrometastases (≤0.2 mm 
versus larger) in predicting the likelihood of involvement of axillary non-SLNs. Guidelines 
from ASCO and NCCN recommend that routine completion ALND be carried out for 
micrometastases detected on SLNB with standard hematoxylin and eosin (H&E) 
examination. However, the indications for a completion ALND for micrometastases are the 
subject of controversy. 
The 2005 American Society of Clinical Oncology (ASCO) guidelines and 2010 National 
Comprehensive Cancer Network (NCCN) guidelines recommend that routine completion 
ALND be carried out for patients with SLNB macrometastases (≥2 mm). However, the 
indications for a completion ALND in patients with <3 positive sentinel nodes is the subject 
of controversy. 
Role of IHC and RT-PCR in sentinel node evaluation — Occult micrometastases refers to 
nodal metastases that are not seen on hematoxylin and eosin (H&E) examination but are 
detected only by immunohistochemistry (IHC) or reverse transcriptase polymerase chain 
reaction (RT-PCR). The significance of occult micrometastases in terms of surgical 
management and patient outcome appears to be negligible. 
Preliminary results from the American College of Surgeons Oncology Group (ACOSOG) 
study Z0010, a prospective multicenter study of 5210 patients with almost eight year follow 
up, confirm that IHC-detected metastases have no significant impact on overall survival. 
Thus, routine IHC or PCR is not recommended for the evaluation of SLNs in guidelines 
published by ASCO, NCCN, and others. Histologically negative nodes that are IHC or RT-
PCR-positive are classified as pN0 disease in the TNM staging system for breast cancer.  
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Role of IHC in invasive lobular carcinoma — Although routine IHC staining with 
cytokeratin is not indicated for most breast cancers, it can be helpful for examination of the 
sentinel nodes in patients with invasive lobular carcinoma since the morphology of lobular 
cancer can be difficult to detect on H&E of axillary lymph nodes. In general, IHC should be 
used to definitively diagnose an area that is suspicious for, but not diagnostic of, lymph 
node metastases on H&E rather than as a routine method of evaluating nodes in cases of 
invasive lobular cancer. 
When should completion axillary dissection be performed? The need for completion axillary 
lymph node dissection (ALND) is dependent upon the SLNB findings. There are some clear 
indications and some settings in which optimal surgical approach is controversial.  
There is general acceptance for the following approaches:  
For patients with a negative sentinel lymph node biopsy (SLNB), completion ALND is not 
indicated. 
Patients with SLNB showing isolated tumor cells only are considered node negative and 
completion ALND is not indicated.  
For patients with a positive SLNB showing micrometastases or macrometastases in three or 
more nodes, detected with standard hematoxylin and eosin (H&E) examination, completion 
ALND is recommended for staging purposes and to ensure local control. The timing of the 
procedure (ie, immediate [one operation] versus delayed [two separate operations]) does 
not seem to impact the total lymph node yield or the rate of long-term complications 
(particularly lymphedema). 
In contrast, the need for a completion ALND is controversial in patients with a positive 
SLNB showing micrometastases or macrometastases in less than three nodes, detected with 
standard hematoxylin and eosin (H&E) examination. The SLN is the sole tumor-bearing 
node in up to 60 percent of cases overall, and in almost 90 percent of patients who harbor 
only micrometastatic disease. These observations have led to speculation that completion 
ALND may not be necessary in selected patients with a positive SLNB in less than three 
nodes because the need for systemic therapy is established and the risk of an axillary 
recurrence appears to be low.  
The ACOSOG Z-0011 trial was designed to address the need for completion ALND for 
patients with T1 or T2 tumors that were clinically node negative and had less than three 
positive sentinel nodes; all patients were treated with radiation to the breast. Target accrual 
was 1900 patients. The study closed prematurely because of low accrual and low event rate 
after enrolling 425 patients in the SLNB alone arm and 388 in the SLNB plus ALND. The 
majority of patients had estrogen receptor positive tumors. At a median follow-up of 6.3 
years, there were no significant differences between the SLNB plus ALND group versus the 
SLNB alone group in the locoregional recurrence rate (in breast recurrence 3.7 versus 2.1 
percent; nodal recurrence 0.6 versus 1.3 percent), overall survival (91.9 versus 92.5 percent) 
or disease free survival (82.2 versus 83.8 percent). Estrogen receptor status and adjuvant 
systemic therapy were independent predictors of survival. 
Based upon the apparent lack of benefit and low risk of events in this trial, some have 
suggested that completion ALND is not necessary for women with T1 or T2 tumors that are 
clinically node negative with less than three positive SLNs who will be treated with whole 
breast radiation, particularly in women with estrogen receptor positive tumors. Others 
prefer to wait for results from two ongoing randomized trials studying the benefit of ALND 
for clinically node negative women with positive SLNs: the EORTC 10981-22023 AMAROS 
trial; and Trial 23-01 of the International Breast Cancer Study Group (IBCSG). 
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Until more data are available, the need for completion ALND in clinically node negative 
women with less than three positive SLNs who will be treated with radiation to the breast is 
best resolved on a case-by-case basis, taking into account the patient’s other risk factors and 
comorbidities and patient preference. When completion ALND is omitted in patients with a 
positive SLNB, radiotherapy is recommended. 
Predictive nomograms — SLNB followed by a completion ALND results in significantly 
greater arm morbidity than SLNB alone. Because the majority of patients with a SLNB 
metastases will not have additional positive nodes on completion ALND, several predictive 
nomograms for estimating the risk of additional positive nodes have been developed in an 
effort to spare women from unnecessary and potentially morbid surgery. These nomograms 
include both clinical and pathologic features, such as the size and/or number of the SLN 
metastases, extranodal extension, and the size and/or presence of lymphovascular invasion 
in the primary tumor. A retrospective analysis of 319 patients with a positive SLNB who 
underwent completion axillary dissection compared the performance of four different 
nomograms. None of the nomograms was sufficiently reliable for clinical use. 
Sentinel lymph node biopsy (SLNB) remains controversial in selected clinical settings. 
Male breast cancer — The vast majority of published studies of SLNB for breast cancer are in 
women. Data are limited in men with breast cancer (MBC), because it is uncommon. A 
retrospective study of 30 men with breast cancer reported a 100 percent SLNB identification 
rate and a false negative rate of 0 percent. Prospective studies establishing the sensitivity 
and specificity of SLNB in MBC have not been carried out. However, the principles guiding 
SLNB in women appear to apply to men. 
Due to the limited amount of data, the 2005 American Society of Clinical Oncology (ASCO) 
guidelines on SLNB did not make a specific recommendation about the use of SLNB in 
MBC, although it was deemed "acceptable". 
Most studies have restricted SLNB to T1 or T2 breast cancers <5 cm in size, since larger 
tumors have a higher likelihood of positive axillary nodes. However, some studies have 
shown that SLNB is accurate in patients with T3 tumors and clinically negative axillae. 
Thus, many clinicians do not recognize large breast tumors as a contraindication to SLN 
dissection, as long as the axilla is clinically negative.  
However, patients with T4 tumors (locally advanced) or inflammatory breast cancer are not 
considered candidates for SLNB. The false negative rate is high in patients with 
inflammatory breast cancer, presumably because of the presence of partially obstructed, 
functionally abnormal subdermal lymphatics.  
The 2005 ASCO guidelines on SLNB did not recommend the routine use of SLNB in patients 
with locally advanced or inflammatory breast cancer for whom ALND was recommended to 
ensure locoregional control. Consensus recommendations from an International Expert 
Panel published in 2010 considered inflammatory breast cancer to be the one of the few 
absolute contraindications to SLNB. In addition, SLNB was not recommended for T4 
tumors. 
Many women with large primary breast tumors are offered neoadjuvant chemotherapy 
prior to definitive locoregional therapy. The optimal timing for sentinel lymph node biopsy 
(SLNB) in patients receiving neoadjuvant therapy has been debated, because some have 
reported a higher false negative rate for SLNB performed after induction therapy. Other 
uncontrolled studies support the accuracy of SLNB in such patients.  
The 2005 ASCO guidelines concluded that there was insufficient information to guide the 
appropriate timing for SLNB in patients receiving preoperative systemic therapy. However, 
www.intechopen.com
 
Sentinel Lymph Node Biopsy: Actual Topics 
 
403 
if prognostic information gained from examination of the axillary nodes is deemed valuable 
for planning locoregional treatment, SLNB can be considered before the institution of 
systemic therapy. Completion axillary dissection, if indicated, can be performed following 
chemotherapy at the time of definitive surgery. The ACOSOG trial Z1071, which is still 
accruing patients, is designed to answer the question of SLNB accuracy after neoadjuvant 
chemotherapy. 
Studies that evaluated the functional anatomy of lymphatic drainage support the theory that 
all quadrants of the breast drain into the same lymph node(s). Thus, subareolar and 
intradermal (rather than peritumoral) injection of radiolabeled colloid or blue dye render 
SLNB feasible for patients with multicentric disease.  
The success of SLNB for multicentric disease has been demonstrated in several studies. In a 
study of 142 women with multicentric breast cancer, SLNB was successful in 91 percent, 
with a false negative rate of 4 percent. However, the number of patients requiring 
completion ALND because of a positive SLN is higher in multicentric compared with 
unicentric disease. The likelihood of finding additional disease at the time of completion 
ALND is also higher with multicentric disease. The ASCO guidelines recommend SLNB as 
appropriate for patients with multicentric disease. 
Most women with ductal carcinoma in situ (DCIS) do not require assessment of the axillary 
nodes, particularly if they are undergoing breast conserving therapy. However, women with 
DCIS may be candidates for SLN mapping if they are undergoing mastectomy, because the 
performance of SLNB will be impossible at a later time if invasive disease is found. An intact 
breast with its lymphatic plexus is necessary for injection of both the blue dye and the 
radioisotope tracers. 
Some recommend that SLNB be considered in patients who are undergoing breast 
conserving therapy or mastectomy for DCIS only if the risk of node metastases is increased, 
as with extensive high-grade DCIS, a strong suspicion of invasive disease based upon 
ancillary imaging, or documented microinvasive disease in the core biopsy. However, if a 
lumpectomy is performed and invasive disease is identified, a SLNB can be done as a 
separate operation. This approach can minimize unnecessary morbidity, since SLNB can be 
associated with complications. SLNB is generally performed if microinvasion is found in the 
breast biopsy or if mastectomy is required for extensive or multifocal DCIS, where the risk 
of an occult invasive component is increased. 
The finding of isolated tumor cell clusters (ie, pN0(i+)) in SLNs from patients with DCIS 
changes the clinical disease stage to stage IB in the seventh edition of the TNM staging 
system. 
The safety and test performance of SLNB during pregnancy has not been fully evaluated. 
Supravital dyes such as isosulfan blue dye should not be administered to pregnant women. 
Available data suggests that the dose of radiation to the fetus is minimal using radiocolloid 
during SLNB. Nonetheless, 2005 guidelines from ASCO recommend against the use of 
SLNB in pregnant women with early stage breast cancer.  
The feasibility of SLNB in women who have undergone other non-oncologic types of breast 
surgery such as reduction mammoplasty or augmentation with breast implants is unclear. 
The expert panel convened by ASCO did not make a recommendation for or against SLNB 
in women who have had breast reduction or augmentation because of insufficient data. 
They suggested that if SLNB were considered in this setting that it might best be performed 
with preoperative lymphoscintigraphy. 
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SLNB after axillary surgery has not been widely studied. In one retrospective series, a SLN 
could not be identified in 25 percent of 32 cases in which SLNB was attempted in women 
who had undergone prior axillary surgery. Guidelines from ASCO recommend against 
SLNB in women who have undergone prior axillary surgery. However, there are 
accumulating reports of successful second SLNB in patients with a local breast cancer 
recurrence following a previous SLNB and/or axillary dissection. This practice is becoming 
more frequently employed and further study is indicated, including the optimal interval 
before repeat sentinel node biopsy should be attempted. Lymphoscintigraphy should be 
performed if repeat sentinel node biopsy is planned, given that these patients often have 
alternate drainage patterns. 
SLN techniques can identify non-axillary metastases in up to 43 percent of cases, depending 
upon the volume and type of colloid injected, injection technique, and primary tumor 
location and size. Whether or not this is useful remains controversial, since the majority of 
the data regarding treatment decisions and outcomes comes from evaluation of only axillary 
nodes. 
Positive IM nodes are most common with medial tumors over 2 cm in size. The clinical 
relevance of finding and treating IM nodal disease in breast cancer is highly controversial.  
Patients with multiple positive axillary nodes usually have the IM node chain included in 
the radiation field, if it can be safely undertaken without a significant dose to the heart. 
However, it remains unclear whether inclusion of the IM nodes in the treatment field is 
responsible for the survival benefit seen with chest wall radiation. Definitive demonstration 
of benefit for the treatment of IM nodes in the radiation field requires a clinical trial in which 
women are randomly assigned to IM-directed RT fields or not. Two such trials have 
completed accrual, and results are forthcoming: one sponsored by the EORTC (protocol 
22922) and the other by the National Cancer Institute of Canada (protocol MA 20).  
Patients with axillary node-negative disease will be found to have regional metastases to the 
IM nodes in 8 to 10 percent of cases. The diagnosis of positive IM nodes might benefit those 
patients who would otherwise not be candidates for adjuvant systemic therapy. Some have 
suggested that patients with primary IM nodal drainage on lymphoscintigraphy receive 
radiation treatment targeting the IM chain. However, many surgeons do not employ 
radiotracer injection and use only an intraoperative injection of blue dye to identify the 
sentinel nodes. Additional noninvasive methods for IM node assessment may be helpful, 
including MRI or PET scanning, although these imaging modalities are unable to 
definitively identify positive nodes.  
There are also limitations to the SLN technique for identification of IM nodes. SLNB does 
not reliably identify involved IM LNs because of interference from radioactivity at the 
primary tumor site. There is a high rate of technical failure (20 to 39 percent) in patients with 
parasternal hot spots on lymphoscintigraphy. In addition, not all hot spots in the IM region 
represent tumor involvement.  
In addition, the IM nodes are difficult to sample surgically if a positive hot spot is identified 
in this area. Although IM biopsy can be accomplished at the time of mastectomy by splitting 
the fibers of the pectoralis major, an IM node biopsy in a patient undergoing breast 
conserving surgery usually requires a second incision, which is cosmetically visible in many 
types of clothing. The procedure can be complicated by pneumothorax, pleural effusion or 
bleeding.  
Not surprisingly, there is disagreement among major groups on the issue of surgical 
management of the IM nodes. There is no consensus on the need for IM nodal dissection in 
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women with detection of an IM SLN. Internal mammary nodes are not routinely dissected 
in patients undergoing breast conserving therapy or mastectomy with axillary lymph node 
dissection. Thus, in the absence of definitive data, dissection of the IM nodes with sentinel 
lymph node biopsy should still be considered investigational. 
Numerous case reports document identification of intramammary lymph nodes on SLNB, 
although few have explored the clinical significance of this finding. Intramammary LNs are 
present in 1 to 28 percent of women with breast cancer. Most series report a high likelihood 
of additional axillary nodal metastases when the intramammary nodes contain cancer. 
If intramammary nodes contain tumor, they have the same prognostic significance as a 
positive axillary LN with respect to staging. ALND should be considered for women with a 
positive intramammary LN on SLNB, even if the axilla is clinically negative, because of the 
high rate of axillary LN involvement in these women. 
Many studies have sought to determine the optimal technique for SLNB. Using a 
combination of isotope and blue dye for sentinel node localisation drastically reduces the 
rates of failed and false-negative procedures. In the ALMANAC study, in most patients both 
dye and isotope found the sentinel nodes, however, in approximately 10% of patients only 
one of the agents located the sentinel node. More importantly, in approximately 4% of 
patients the positive SLN was found by dye alone and in 3% by isotope alone; these would 
have been missed by relying on a single technique of localisation. 
They have shown previously that replacement of the SLN by tumor significantly reduces the 
radioisotope uptake and may adversely affect intra-operative SLN identification. However, 
SLN identification using blue dye is not compromised by increased SLN tumor burden. The 
afferent lymphatic leading to the blocked node may be patent. The surgeon can identify the 
tumor-replaced node by following the blue lymphatic leading to the node. This result 
further suggests that a combination of blue dye and radioisotope should be used to optimise 
the localisation rate. 
The ALMANAC study found that patient age, BMI, sentinel node visualisation on pre-
operative lymphoscintiscan, tumor location, tumor size, tumor histology and presence of 
multifocality did not alter the false-negative rate. They have shown that high BMI adversely 
influences the successful mapping of SLNs. Patient age did not alter SLN localisation, 
though it has been reported in several other studies which have shown that accurate 
identification of the SLN decreases with increasing age as well as weight. The specific causes 
for mapping failure in overweight patients are unclear. Sentinel node identification may be 
difficult in obese women because of the higher content of subcutaneous and axillary adipose 
tissue. Furthermore, the increased fatty tissue may impede the flow of the tracer through the 
lymphatics in the breasts of these patients. Or the lymph nodes in obese patients may have 
undergone fatty degeneration reducing their capacity to concentrate the tracer. These 
findings, however, do not contraindicate SLNB in obese individuals as the rate of successful 
localisation remains high and unsuccessful mapping does not adversely affect their 
prognosis or treatment. 
Arguments have been made in favour of pre-operative lymphoscintigraphy as a road map 
for surgeons. The ALMANAC results indicate that SLN visualisation on preoperative 
lymphoscintigraphy significantly improves the intra-operative SLN identification rate 
(p<0.001). If an SLN takes up enough radiocolloid to image with a camera, it should  
be easily detected with the intraoperative probe. Similar findings were reported by Birdwell 
et al. 
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They also found that tumors located in the upper outer quadrant had a higher SLN 
identification rate compared to other tumor locations. The simplest explanation relates to the 
transit distance for the blue dye or radioisotope from the peritumoral injection site to the 
axilla. 
High false-negative rates may have a direct adverse impact on patient care including 
accurate staging, treatment decision making and long-term outcomes including survival. 
Clearly, the potential for both local as well as systemic under-treatment of patients increases 
as the false-negative rate increases. The ALMANAC study demonstrates a reduction in the 
predictive value of a negative SLNB in grade 3 tumors. Grade 3 tumors have a higher 
incidence of nodal metastases, thereby have an increased risk of lymphatic obstruction and 
re-routing of tracer leading to a false-negative result. Therefore, caution is required when 
applying the SLNB procedure in patients at considerably increased risk for lymph node 
positive disease. 
The data from this study suggest that surgeons should not stop after finding just one SLN 
but should search thoroughly to be certain there are not more. This is important as the false-
negative rate in patients who had multiple sentinel nodes (3 or more) removed was 1.1% 
compared with 10.1% in those with 1 sentinel node removed. 
Then, sentinel node biopsy is a safe and accurate alternative to routine axillary dissection for 
patients with early stage breast cancer with clinically negative axillary nodes. The success 
and accuracy of sentinel node mapping in breast cancer is optimised by the combined use of 
blue dye and isotope. Body mass index >30, tumor location other than upper outer quadrant 
and non-visualisation of SLN on pre-operative lymphoscintiscan adversely affect the SLN 
identification rate. SLNB may not be appropriate for patients who have grade 3 tumors, and 
the decision to perform the procedure should be determined on the basis of the clinical 
judgement of the treating surgeon. 
3. Hypersensitivity reactions and blue dye 
Hypersensitivity reactions to anesthetics and associated agents used during the 
perioperative period have been reported with increasing frequency in most developed 
countries. Their estimated incidence ranges between 1 in 5000 to 1 in 13,000 anesthetics 
(Mertes et al., 2002).  Although neuromuscular blocking agents, latex, and antibiotics are the 
leading causative agents, every substance used during the perioperative period can be 
responsible for an immediate hypersensitivity reaction. (Mertes et al., 2003)  
The combination of isotope and blue dye is the current recommended technique for sentinel 
node localization in breast cancer in many countries with localization rates of over 99%. 
However, blue dye is associated with a range of allergic reactions. There have been a 
number of case reports and single case series of anaphylactic reactions following 
administration of patent blue V. Its allergic potential is also reflected in reports to the 
Committee of Safety of Medicines and to the manufacturer. No mortality has been reported 
but two cardio-respiratory arrests have been attributed to patent blue V (Mansel et el ., 2006; 
Montgomery et al., 2002). 
Since the 1960s, blue dyes have been used in a variety of clinical situations, ranging from 
cardiac output determination (Al-Fadly et al., 1956) and lymphangiography (Biran et al., 1973) 
to intraoperative lymphatic mapping and sentinel lymphadenectomy in various types of 
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neoplasms (Bilchik et al., 1998). They have long been considered a rare cause of anaphylaxis. 
This might in part be due to misleading nomenclature (Scherer et al., 2006). Patent BlueV (also 
called E131,Acid Blue 3, and disulfine blue) and isosulfan blue (also called Patent Blue violet or 
Lymphazurin),which belong to the group of triarylmethane dyes and share the same formula, 
are the most commonly used . A recent literature review that includes various names of these 
dyes reveals an impressive number of case reports of hypersensitivity reactions (Cimmino et 
al., 2001), and it has been suggested that sensitization occurs with everyday products 
containing blue dyes (Kalimo et al., 1981). In view of the increasing use of blue dyes for 
lymphatic mapping for sentinel lymph node biopsy, the incidence of anaphylaxis to these 
drugs can be expected to increase. Based on several retrospective and prospective studies, the 
estimated incidence of reactions of all grades of severity varies between 1% and 2%, with 
severe reactions being observed in 0.2% to 1.1% of cases (Cox et al., 2000; Montgomery et al., 
2002; King et al., 2004; Albo et al., 2003; Blessinget al., 2002). In a series of 1013 patients, 
preoperative prophylaxis with glucocorticoids, diphenhydramine, and famotidine was found 
to reduce the severity but not the overall incidence of adverse reactions to dye (King et al., 
2004). Similarly, a nonsignificant trend toward fewer allergic reactions with smaller volumes of 
blue dye has been reported (Raut et al., 2006). 
The clinical diagnosis of an immediate hypersensitivity reaction during anesthesia is 
generally considered difficult. Many signs can be misinterpreted as an interaction between 
the clinical status of the patient and the drugs administered a dose-related side effect of the 
drugs, or excessively light anesthesia. Vigilance is essential because reactions might be well 
established before they are detected. Therefore information concerning the various clinical 
features encountered is essential, particularly when reactions caused by injected dye are 
considered. Indeed, the clinical diagnosis of anaphylaxis is, in fact, presumptive based on a 
close temporal relation with the administration of the implicated substance. This is clearly 
not the case for hypersensitivity reactions elicited by dyes. In general, the clinical reactions 
respond to the definition of an ‘‘immediate’’ reaction occurring within less than 1 hour after 
exposure, they significantly differ from those caused by neuromuscular blocking agents or 
antibiotics, which usually occur less than 10 minutes after intravenous administration in a 
sensitized patient (Mertes et al., 2003). 
We recall that allergic reactions are classified into four grades (Montgomery et al, 2002): 
 grade I corresponds to the cutaneous signs generalized erythema, urticaria with or 
without edema angioedema;  
 grade II is a multi-organ damage moderate with cutaneous signs, hypotension but 
greater than 70 mm Hg and tachycardia unusual bronchial hyperreactivity (cough, 
difficulty breathing); 
 grade III corresponds to a multiple organ damage severe threat ¸ ant life and requiring 
special treatment; collapse, tachycardia or bradycardia, heartbeat, bronchospasm. 
Cutaneous signs may be absent or appear after the Remon-Wu blood pressure; 
 grade IV corresponds to circulatory arrest and / or respiratory. 
The mechanism underlying the allergic reaction to blue dyes remains unclear. Both direct 
mast cell activation, basophil activation, or both and cross-linking of specific IgE antibodies 
are possible causative factors (Woltsche-Kahr et al., 2000).  
In conclusion, the use of Patent Blue V for localization of sentinel lymph nodes is associated 
with a significant number of hypersensitivity reactions. Many groups around the world are 
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doing protocols to identify a patient that will be affected with hypersensitivity reaction after 
the use of blue dyes (Mansel et al., 2003). Maybe, with the development of new markers 
with less risk, we`ll find a solution for this. 
4. Sentinel lymph node biopsy: What's new? 
Cancer is known to develop via a multistep carcinogenesis process. Cancer treatments are 
performed on the basis of clinical and pathologic staging that is determined using 
morphologic diagnostic tools, such as conventional radiological and histopathological 
examinations (Pinheiro et al., 2000). Sentinel node localization is one the most important 
parameters considered in cancer diagnosis and therapy. The concept of the sentinel lymph 
node has earned widespread importance with the advent of the sentinel lymph node biopsy 
technique. This technique has been explored in staging of various types of cancers to 
determine their spread. Recent advances in molecular, biological, and genetic diagnostic 
techniques have led to a considerable exploration of the sentinel lymph node diagnostic 
agents and modalities and their implication for the involvement of Sentinel node in 
development and progression of cancer. 
In the last decade, methods for the precise localization of sentinel lymph node (SLN) have 
drawn tremendous attention by cancer surgeons and researchers in the field of medical 
diagnosis. The accurate identification and characterization of lymph nodes by imaging has 
important therapeutic and prognostic significance in patients with newly diagnosed cancers. 
Amongst the various exploited methods for SLN diagnosis, nanocarriers have received 
increasing attention as lymph node delivery agents. The present review will focus on 
various such particulate carriers namely radiolabeled sulfur colloids, liposomes, quantum 
dots, dendrimers and magnetic nanoparticles, which are most extensively studied and have 
been attributed with the most desirable characteristics for SLN imaging (Ratnesh et al., 
2009). 
Nanotechnology, one of the recent leaps in technology progress, has provided a big boost to 
sentinel lymph node imaging. The most important advantage of nanocarriers in this regards 
is their ability to enable the targeted delivery of imaging agents for specific sentinel lymph 
node imaging. Accurate and quick identification of Sentinel node has now been rendered as 
an achievable target due to the advances in nanotechnology. For example, the use of 
Quantum dots (Chan et al., 2002), potentially allows rapid and accurate sentinel lymph node 
localization. sentinel lymph node imaging using several types of nanocarriers has been 
investigated and systematic investigation of these carriers is a need of the hour. Quantum 
dots have been used as fluorescent imaging agents for the in vivo imaging of sentinel lymph 
node. Conjugation of Quantum dots with biomolecules, including peptides and antibodies, 
has been used to target tumors in vivo. Quantum dots have also been employed to identify 
metastatic cancer cells, quantitatively measure the level of specific molecular targets and 
guide targeted cancer therapy by providing biodynamicmarkers for target inhibition. 
Amongst the other nanocarriers explored, dendrimers have displayed long circulating 
positive contrast enhancement by MRI/ NIR imaging in various animal models (Bellin et al., 
1998). These investigations suggest the possibility of utilizing a labeled MRI/NIR optical 
hybrid contrast agent containing nanocarrier for sentinel lymph node imaging. Recent 
animal studies with targeted nanobubbles (Dayton et al., 2001) for lymph node imaging and 
therapy have exhibited a significantly improved therapeutic efficacy of these carriers when 
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compared with the nontargeted nanoparticles. This nanocarrier formulation offers the 
advantage of providing real-time reports of the treatment by means of ultrasound imaging 
since the nanocarrier contains both the imaging as well as the therapeutic agent. 
The development of multifunctional nanoparticles may contribute significantly to the 
localization of sentinel lymph node in multiple types of cancer. Ideally, for constructing 
multifunctional nanoparticles, an appropriate combination of agents (imaging agent and 
targeting moiety) will have to be chosen, based on accurate biological information within 
the tumor and lymph node with imaging material attached on the nanoparticle surface 
(Forsberg et al., 2001). Nanoparticles may eventually be capable of detecting sentinel lymph 
node, pinpointing and visualizing their location in the body (real-time in vivo imaging). 
This advancement may eventually lead to complete elimination of cancerous cells identified 
by accurate sentinel lymph node localization. Several types of nanocarriers have been 
evaluated to identify their potential for sentinel lymph node imaging. 
Despite all the new initiatives in the sentinel lymph node biopsy, it was never published a 
novel marker derived from blood for replacing the blue dye (Pinheiro et al., 2009), a member 
of the current gold standard with the technetium. 
During the management of two patients submitted to breast biopsy in our service,  
we observed their skin mapped as the lymphatic ducts draining to axillary lymph nodes 
(Photo 1).  
 
 
Photo 1. Skin mapped as a lymphatic duct in direction to the axilla 
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This observation stimulated us to try an animal model which was described for our group. 
Our theory was that some blood derivate (hemosiderin) was captured by macrophages and 
accessed the lymphatic duct in direction to the axilla.  
In bid to replicate what was seen in patients, we developed an experimental protocol for 
obtaining a marker derived from blood and tested in a model of experimental surgery in 
dogs (Photo 2).  
 
Photo 2. Sentinel lymph nodes marked with hemosiderin at left and with patent blue at 
right. Non-sentinel lymph node in the middle. 
We found statistically significant and consistent data when comparing the group that 
underwent patent blue / technetium versus the group undergoing autologous blood-
derived marker / technetium (Pinheiro et al., 2010). 
The results of our experimental work showed that the blood derivate (hemosiderin) was 
capable of being used along with the radiomarker (technetium 99m) and coloring 
wonderfully the sentinel lymph node of female dogs.  
The use of the blood derivate (hemosiderin) with the radiomarker also showed equal results 
comparing the use of the patent blue with the radiomarker in identifying the mammary 
sentinel lymph nodes of the female dog because they were always found in both axillas.  
The hemosiderin, a blood-derived marker, theoretically does not cause side effects as 
allergic reactions. Besides, it may decrease personal and healthcare spendings, reduce the 
morbidity of the procedure and the emotional suffering, along with other indirect vantages. 
4.1 Lipossomes 
Liposomes have been used as delivery vehicles since the 1960s and their use for the delivery 
of imaging agents, for all imaging modalities, has a long history. Liposomes are defined as 
vesicles in which an aqueous volume is entirely surrounded by a phospholipid membrane. 
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They can vary in size from 30 nm to several micrometers, and can be uni- or multilamellar. 
Their properties have been extensively investigated and can vary substantially with respect 
to their size, lipid composition, surface charge, and method of preparation. 
Currently, liposomes are one of the most widely explored nanocarriers for delivering 
imaging agents to the SLNs. Many imaging agents can be covalently or non-covalently 
incorporated into the different compartments of these nanocarriers. Also, they can be 
designed to encapsulate a wide range of hydrophilic agents (dyes, drugs etc) within their 
aqueous interior. They also serve as promising lymphoscintigraphic agents since their 
surface can easily be modified by attaching or coating with specific receptors or other 
molecules such as polyethylene glycol (PEG) for selective targeting. The relative efficiency of 
entrapment of imaging materials into these nanocarriers has been established. Liposomes 
have also been used for cellular labeling of contrasting agents such as iron oxide 
nanoparticles to facilitate enhanced imaging. Literature also reports loading of liposomes 
with gamma-emitters and other radionuclides as well as specific receptor targeting ligands 
for application in various imaging modalities to facilitate diagnostic imaging of liver, spleen, 
brain, cardio-vascular system, tumors, inflammation and infection. 
Liposomal carriers for lymph node drug delivery were first investigated by Segal et al., 
where an intratesticular injection of liposomes, encapsulating the anticancer drug 
actinomycin D, was carried out. Lymph node imaging using 99mTc-labeled liposomes was 
first performed by Obsorne et al. Although several clinical studies were performed soon 
after these initial attempts and reported promising results, the use of 99mTc-liposomes for 
lymphoscintigraphy was questioned in an article by Patel et al. in 1984. In this report the 
stability of the 99mTc-liposome complex as well as the integrity of the liposomes with in the 
lymph nodes was put under surveillance. 
The early liposome involving imaging studies employed stannous chloride as a reducing 
agent to associate reduced 99mTc with the liposomal surface. This labeling method was 
subsequently shown to be unstable in vivo and lead to the development of more effective 
liposome labeling methods. Another major drawback which hampered the successful 
liposome targeting to the SLN was the lack of effective preoperative staining of regional 
lymph nodes to improve their intraoperative identification and thus the selectivity of 
‘sentinel node’ lymphadenectomy. Unfortunately the most commonly used staining agent, 
blue dye, used in these early trials failed to provide the requisite intensity and duration of 
contrast, for enhanced imaging. 
Since then several attempts have been made by researchers all over the world towards the 
development stable and effective liposome/99mTc-liposome based SLN imaging agents to 
tackle the afore-mentioned problems. One of these early development trials by Hirnle et al. 
utilized blue dye-encapsulated liposomes to localize the SLNs during surgery. 
With this technique, it was studied that following the injection of the blue liposomes into the 
lymphatic vessels, the lymph nodes were stained blue. Most notably, retroperitoneal lymph 
nodes in rabbits remained dark blue up to 28 days after the hind limb endolymphatic 
instillation of liposomal blue dye. Promising results of these studies further paved a way to 
human trials, in which blue liposomes were injected directly into the lymphatic vessels of 
the foot of a patient prior to retroperitoneal staging-lymphadenectomy. Twenty four hours 
after the intralymphatic injection of the blue liposomes, when a surgery was performed, the 
lymph nodes were well stained with the blue dye and were readily visualized. 
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These investigations proved the potential of liposomes as promising carriers for SLN 
imaging. However, the relatively low retention of liposomes in lymph nodes led to further 
investigations to improve this limitation. 
4.2 Dendrimers 
Dendrimers are perfectly cascade-branched, highly defined macromolecules, characterized 
by a combination of high end group functionality and compact molecular structures. The 
two major strategies of dendrimer synthesis in laboratories were initiated back in the year 
1979. 
The first method process included outward branching of an initiator core by a sequence of 
iterative reactions resulting in a three-dimensional organization of terminal groups. Fréchet 
et al. established the second process, known as the convergent growth process, which 
progressed inward from what would seem as a dendronmolecular surface to a reactive focal 
point at the root. The reaction of several, resulting reactive dendrons with a multifunctional 
core resulted in the formation of a dendrimer structure. The first dendrimer family, which 
was synthesized by structuring concentric shells of dendritic ǃ-alanine units around a 
central initiator core, was the PAMAM (polyamidoamine) dendrimers. 
These core–shell dendrimers grew linearly in diameter as additional shells/generations 
were added to their architecture. At the same time, at each generation, the surface groups 
underwent exponential amplification based on the dendritic-branching mathematics. 
Progression of this process over a few generations resulted in the formation of 
‘geometrically closed’ nanostructure with guest–host container characteristics. Research 
over the years has resulted in the production and characterization of fifty such other 
dendrimer families, possessing interiors of varying compositions such as carbon, nitrogen, 
silicon, sulfur, phosphorus or metals. The architectural diversity of these nanostructures 
resulted in their application in biomedical functions including diagnostic imaging. 
Distinctive sizes, well defined structural design and the abundance of reactive and 
accessible peripheral functional groups were some of the features of this family of diagnostic 
vehicles which captured the interest of imaging experts. Other noteworthy features 
desirable for these applications included: structural control over size and shape of imaging-
agent cargo space; biocompatibility; non-toxicity of the polymer/pendant functionality 
employed; nanoscale-vehicles and/or scaffolding properties with high imaging-agent 
capacity; lack of immunogenicity; appropriate cellular adhesion; endocytosis and 
intracellular trafficking to allow imaging in the cytoplasm or nucleus; acceptable 
bioelimination or biodegradation; minimal nonspecific cellular and blood-protein binding 
properties; ease of consistent, reproducible, clinical grade synthesis. 
In view of these valuable traits, several research groups have been actively engaged in 
designing dendrimers for diagnostic applications. 
Dendrimers bearing GdIII complexes are being used as imaging agents in magnetic 
resonance imaging. Pioneering work in this area has been carried out byWeiner et al. This 
research group has reported dendrimer-based GdIII chelates consisting of polyamidoamine 
(PAMAM) dendrimers of generations 2 (G2) and 6 (G6), and possessing 12 and 192 reactive 
terminal amines, respectively, conjugated to the chelating ligand 2-(4-isothiocyanatobenzyl)-
6-methyldiethylenetria minepentaacetic acid (DTPA), through a thiourea linkage. 
In vivo experiments on rabbits have revealed that intravenous injections of larger dendrimer 
conjugates provides enhanced circulation times of these structures of greater than 100min 
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thus resulting in excellent MRI images of the blood vessels. Another interesting area of 
research included the construction of DNA dendrimers which were synthesized by 
sequential hybridizations of partially complementary heteroduplexes (DNA monomers). 
After each generation, the structure was fixed by a crosslinking step. These DNA 
dendrimers were employed for high sensitivity detection of oligonucleotides since 
numerous radioactive or fluorescent labels could be tagged subsequent to the modification 
of the terminal polynucleotide strands. Such DNA dendrimers with capacity of selective 
recognition of specific RNA strands have been employed as selective markers of the 
Epstein–Barr virus in post transplant patients. Polynucleotide dendrimers labeled with 
fluorescent tags have also been proved as promising tools in DNA microarray technology 
for signal amplification in high-throughput functional genomic analysis. 
Rapid diagnosis of genetic and pathogenetic diseases has been made possible by dendrimer-
based biosensors for DNA hybridization. The single-stranded oligonucleotides immobilized 
on these structures specifically hybridize with their complementary target sequence. Also 
PAMAM dendrimers loaded with 111 In or 153 Gd complexes have been used as the 
anchoring vehicles for highly specific, radiolabeled monoclonal antibodies. In yet another 
study, the dendrimer arms were tagged with dye molecules which upon hybridization with 
a complementary fluorescently labeled DNA strand, generated energy transfer to provide 
enhanced imaging. 
The first dual purpose dendrimers loaded with MRI-fluorescent imaging agents were 
described by Talanov et al. where PAMAM dendrimers were covalently attached to GdIII–
DTPA chelates and units of the NIR fluorescent dye, Cy 5.5. In these systems, the bifunctional 
DTPA derivative, 2-(4-isothiocyanatobenzyl)-6-methyldiethylenetriaminepentaacetic acid 
(1B4M-DTPA) was chosen as the sequestering agent for GdIII , whereas the cyanine dye, Cy 
5.5, was included to facilitate NIR imaging. These systems resulted in clear magnetic resonance 
and fluorescence images of the SLN(s). These dendrimers resulted in enhanced optical 
imaging, despite their powerful enhancement in the NIR, thus allowing the node localization 
through the skin. The blurred imaging by OI was taken care of by MRI which enabled the 
visualization of the node as well as its associated lymphatic channel. The superficial location of 
the node, in this study, resulted in the visualization of both the afferent and efferent lymphatic 
channels in the fluorescent image of the surgically exposed tissues. The research clearly 
demonstrates the immense potential of dendrimers as a platform for the development of 
efficient imaging agents for both magnetic resonance and optical imaging modalities. 
Parallel work on the development of such dual mode dendrimers has also been reported by 
Koyama et al. where they have described the successful synthesis and utilization of dual 
labeled MRI/NIR optical hybrid contrast dendrimers for reoperative and intraoperative 
localization of SLNs. Yet another application of dendrimers in diagnostics is their 
application in dynamic MR lymphangiography. Gd-labeled dendrimer-based imaging 
agents have been used in mice models to detect the location of the SLN as well as to 
diagnose the presence or absence of metastatic cancer. Waldmann et al. have shown 
PAMAM-G6 dendrimers to be one of the best MRI imaging agents since they provide high 
concentrations of GdIII within the node, even in the presence of lymph node metastases. 
These dendrimers exhibited most rapid and intense enhancement as compared to the other 
lymphatic agents tested. This utility of G6 dendrimers for lymphatic draining tumors opens 
up yet another avenue of their application for regional lymph nodes. However the 
widespread use of G6 dendrimers is limited due to certain drawbacks. 
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For instance their application may be restricted in overt lymphatic metastases, where the 
metastases can obstruct lymphatic flow, leading to collateral lymphatic circulation, and thus 
prevent the dendrimers from entering into the SLN. 
Another limitation is that since the GdIII concentrations within the lymph nodes are 
estimated based on both phantom studies and T1 measurements, it could not be accurately 
calculated based on relaxivity in the lymph node tissue. Since the tissue in the lymph node is 
not as homogenous as serum phantoms, this non-homogeneity was found to change the 
relaxivity of G6 and affect the T1 signal intensity due to susceptibility artifacts. However, 
since the values obtained with two different methods were nearly consistent, these MRI 
methods were deemed to provide a close estimation to the actual concentrations of GdIII 
within the lymph nodes, although the validation of this estimationwas found to be difficult 
in case of the lymph node specimens, which were too small to be resected and accurately 
weighed. The study thus revealed that the PAMAM-G6 Gd dendrimer not only provided 
excellent opacification of SLNs but also acted as potential carriers for targeted SLN therapy. 
Intensive research in the area of dendrimers as a potential tool for SLN imaging has thus 
revealed that certain pervasive biological patterns and biomimicry have played a distinctive 
role in the development of many biomedical applications for dendrimers. Research in this 
area has gained a huge momentum and around 3000 papers and patents about dendrimers 
as biomedical tools have been published in just last 5 years. The structural preciseness and 
control, reproducible and convenient size scale and comparable physico-chemical properties 
as that of globular proteins, antibodies and enzymes support the potential application of 
these tools in diagnostic imaging, particularly SLN imaging. This gamut of unique 
diagnostic properties offered by the dendrimers, along with their possible application in 
proteomics, clearly indicates their huge potential in the development of new biomedical 
devices and approaches for the detection and treatment of human diseases. 
4.3 Quantun dots 
Quantum dots (QDs) are nearly spherical semiconductor particles with diameters between 
2–8 nm and containing roughly 200–10,000 atoms. They are generally composed of atoms 
from group II and VI elements (e.g. CdSe and CdTe) or group III and V elements (e.g. InP 
and InAs) of the periodic table. The semiconducting nature and the size-dependent 
fluorescence of these nanocrystals have rendered them an extremely attractive approach for 
use in optoelectronic devices, biological detection, and also as fundamental prototypes for 
the study of colloids and the size-dependent properties of nanomaterials. 
QDs provide a new class of biomarkers that could overcome the limitations of conventional 
diagnostics. Thus their application as luminescent imaging probes has significantly 
increased in the recent times. 
When compared to the currently employed diagnostic techniques, QD based detection is 
rapid, easy and cost effective. The unique properties which make them ideal for use in 
diagnostics, include intense and stable fluorescence for a longer time; resistance to 
photobleaching, large molar extinction coefficients and highly sensitive detection due to 
their ability to absorb and emit light very efficiently. Due to their large surface area-to-
volume ratio, a single QD can be conjugated to various molecules, thus making QDs 
appealing for employment in the fabrication of more complex and multifunctional 
nanostructures. 
QDs have been covalently linked to a variety of biomolecules such as antibodies, peptides, 
nucleic acids and other ligands for fluorescence probing applications. Some of the 
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applications of QDs in biology along with their tremendous potential for in vivo molecular 
imaging have already been explored. One of the greatest advantages which makes them 
suitable for imaging in living tissues is that their emission wavelengths can be tuned 
throughout the near-infrared spectrum by adjusting their composition and size, resulting in 
photostable fluorophores that are stable in biological buffers. 
One of the first in vivo applications of quantum dots included mapping of the 
reticuloendothelial system (RES) and localization of SLNs. Fluorescence imaging provided a 
simple optical readout, a higher resolution as well as a wider dynamic range than dye 
absorption or scientigraphy techniques. For exposed tissues, the localization capability and 
sensitivity by QDs were found to be potentially better than those obtained by either visible 
dyes or radioactives, especially when using near-infrared emission. This could be attributed 
to the good tissue penetration and lowered background in the infrared offered by QDs. 
Near-infrared (NIR) fluorescent QDs have been used for SLN mapping and resection. NIR 
light, otherwise invisible to the human eye, provides extremely high signal-to-background 
ratios without changing the look of the surgical field. A thorough discussion of the use of 
NIR light in biomedical imaging has been published previously. 
With a suitable intraoperative imaging system, the NIR QDs provided several advantages 
for SLN mapping which included high sensitivity, real-time and simultaneous visualization 
of both surgical anatomy and lymphatic flow and non-radioactive detection. Kim et al. 
explored the possibility of employing NIR QDs emitting at 850 nm for SLN mapping. In this 
investigation, QDs injected intradermally into live mice were followed in real-time even up 
to 1 cm below the skin in the SLN. A series of 3D MR lymphangiograms recorded at 24 min 
after injecting G6 nano-size contrast agents. Possible accumulation of high concentrations of 
Gd(III) within the nodes as indicated by the phantom having 400 and 800 ppm of Gd(III) of 
the G6 agent. 
In yet another study in pigs, the quantum dots were introduced into the lungs as a method 
of finding the SLN draining from lung cancer. The lymph node draining from the lung was 
rapidly identified. This rapid SLN identification using a non-radioactive method was 
thought to attribute a significant advantage to the method. 
Various studies have been carried out for exploring the application of different materials 
that could be used in the fabrication of either the QD surface or core. Quantum dots with a 
core/shell/shell structure consisting of an alloyed core of InAsxP1-x, an intermediate shell 
of InP, and an outer shell of ZnSewere developed by Kimet al. Here, the cores contained a 
zinc blend structure for all compositions and exhibited a tunable emission in the NIR region. 
The first shell of InP was instrumental for bringing about a red-shift and subsequent 
increase in quantum yield, while the final shell of ZnSe stabilized the system for 
applications in aqueous environments, including NIR biomedical fluorescence imaging. This 
NIR-emitting core/shell/shell In AsxP1-x/InP/ZnSe was successfully used in SLN 
mapping experiments in various animal models. 
In a recent study, PEG-coated quantum dots with terminal carboxyl, amino, or methoxyl 
groups have been used for SLN imaging. After injection, these quantum dots were shown to 
rapidly migrate to SLNs. At least two nodes could usually be defined when their passage 
from the tumor through lymphatics to adjacent nodes was visualized dynamically through 
the skin. Also, imaging studies performed during necropsy confirmed the confinement of 
quantum dots to the lymphatic system and thus proved them to be effective markers of SLN 
pathology. 
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Several studies have been carried out to determine the in vivo fate of QDs. In one such 
investigation, within minutes of intradermal injection into female SKH-1 hairless mice, the 
highly UV fluorescent QDs could be observed moving from the injection sites, through the 
lymphatic duct system to the regional lymph nodes. These results indicated the potential of 
sentinel organs as effective locations for monitoring the transdermal penetration of these 
systems. 
All these investigations have led to the emergence of QDs as technological conjectures with 
characteristics that could greatly improve SLN imaging and detection. However future 
concerted efforts are required in this promising area of research. Some of the important 
considerations which could be focused in future studies include: 1. Overcoming the 
possibility of toxicity from the heavy metal, particularly cadmium, which forms a major 
component of these systems. Toxicology investigations including their distribution, 
excretion, metabolism, pharmacokinetics, and pharmacodynamics would be imperative for 
the development of novel and more effective QDs for application in SLN imaging and 
beyond. 2. Combining quantum dot fluorescence imaging with other noninvasive 
techniques (e.g., scientigraphy, MRI, or PET) would allow mapping of deep nodes and more 
detailed information about SLN. 3. Quantum dots conjugated to appropriate ligands and 
fluorescing at different wavelengths could be explored to localize metastases in SLNs. 4. 
Development of biocompatible QDs with specificity may be explored to avoid their 
nonspecific organ uptake and RES scavenging. They could thus provide a better clinical 
option for effective imaging of SLN. 5. Optimizing the size, shape, and surface chemistry of 
QDs may lead to the development of novel QDs with enhanced and specific applications. 
4.4 Nanoparticles 
Nanoparticles have now been developed as widely used diagnostic agents in medicine. 
They possess unique features that can be exploited to suit the various imaging modalities. 
Many types of nanoparticles exhibit significant retention, sometimes as high as 40%, in the 
first lymph node that they encounter during their movement from the injection site. This 
makes them ideal system for enhanced identification and localization of SLNs. Various 
studies had been reported for SLN imaging using different types of nanoparticles. 
4.4.1 Radiopharmaceutical colloidal nanoparticles 
Radiopharmaceutical colloidal preparations were developed soon after World War II. In 
1955, Hultborn et al. reported the preoperative use of interstitial colloidal gold injections in 
breast cancer patients. With future investigations, 99mTc was introduced as a replacement 
for radioactive gold since it is readily available, inexpensive and has ideal imaging and 
dosimetry characteristics when compared to the latter. The standard radiopharmaceutical 
nanoparticles range in size from 10 nm to 1000 nm and are clinically approved for use as 
imaging agents. 
However, numerous other radiopharmaceuticals have also been reported for this purpose 
which include 99mTc-labeled dextran, 99mTc hydroxy ethyl starch, 99mTc human serum 
albumin (HSA) and several labeled colloids, including gold-198-colloid, 99mTc stannous 
phytate, 99mTc antimony trisulfide colloid, 99mTc rhenium colloid and 99mTc colloidal 
albumin. However, none of these entirely fulfill the desired criteria of an ideal imaging 
agent. The search for an optimal nanoparticulate radiopharmaceutical is still in progress. 
The most essential requirement for SLN detection is that, the developed colloids should 
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move to the SLN with minimal further migration. However most of these nanoparticulate 
systems are not ideal agents for the detection of the SLN, due to the retention of the majority 
of the injected dose at the peritumoral site of injection. 
Studies in animals have demonstrated a very low clearance with less than 5% of the injected 
dose being cleared from the site of injection within the first 60 min and less than 2% of the 
injected dose accumulated in the SLN at 60 min. The resulting low intensity of the 99mTc 
activity frequently makes the SLN localization difficult, either by imaging or with a 
handheld detector probe used in surgery. Filtered particles have been used for 
greatermovement although there is still a debate as to whether filtered particles are better 
than standard particles due to the possible loss of imaging agents during filtration. 
The retention of nanoparticles in the first lymph node is mainly due to phagocytosis of the 
nanoparticles by macrophages. The total retention in the sentinel node is higher than the 
retention in the subsequent draining lymph nodes, since only a very small fraction of 
nanoparticles encountered in various studies led to the introduction of radioactive 
technetium-99m-sulfur colloid particles (99mTc-SC) particles as yet another method to 
localize the SLN in addition to the blue dye being conventionally used by the surgeons. The 
use of 99mTc-SC, in addition to blue dye resulted in a significant improvement in the 
quality of image over, that obtained by the use of blue dye alone. The blue dye was not well 
retained in the SLN and moved very rapidly, thus creating a difficulty for the surgeons to 
distinguish the sentinel node from the secondary lymph nodes. This problem was solved by 
the additional use of 99mTc-SC which proved to be a better marker of the sentinel node. 
Although the blue dye provided the desired visual guide for the surgeon, the inclusion of 
99mTc-SC provided the desired verification that the correct lymph node was biopsied. As 
the imaging could be performed in the operating room prior to and during the surgery, it 
frequently led to a smaller operative incision and decreased the time span required for 
locating the sentinel node. The use of radiolabeled nanocolloids along with the blue dye 
thus proved to be complementary imaging agents which performed the best when used 
simultaneously. 
4.4.2 Magnetic nanoparticles 
The application of magnetic nanoparticles in combination with the other imaging modalities 
is gaining a major momentum in diverse areas of biology and medicine. Unlike many of the 
newer probes used in the field molecular imaging, the magnetic nanoparticles are 
chemically similar to a large number ofmaterials with a long history of clinical use. 
Magnetic nanoparticles consist of a core of superparamagnetic iron oxide (usuallymagnetite, 
Fe3O4, ormaghemite, Ǆ-Fe2O3) and are coated with a biocompatible polymer, and to this 
basic design, biomolecules are attached. Polymer-coated iron oxides have been used in the 
treatment of iron anemias since the 1960s. 
Magnetic nanoparticles can be broadly categorized into two basic types namely the polymer 
coated and the molecularly targeted. Polymer-coated magnetic nanoparticles are those that 
are not designed to be recognized by a specific biomolecule (e.g. receptor, antigen). 
“Molecularly targeted” magnetic nanoparticles are those that are designed to bind to a 
specific target, typically by the attachment of a biomolecule (antibody, peptide, 
polysaccharide). Dextran-coated magnetic nanoparticles (SPIOs) were first introduced for 
hepatic imaging. Following the intravenous injection, these particles have been reported to 
be rapidly taken up by the liver Kupffer cells and appear hypointense or black on the MR 
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images. Subsequently ultra-small magnetic nanoparticles (often referred as USPIOs) were 
developed, that displayed a longer blood half-life, and were taken up by the macrophages 
including those in lymph nodes. 
Superparamagnetic particles (USPIOs) find preferential application in SLN imaging, due to 
the fact that they behave non-magnetically when they are not under the influence of an 
external magnetic field, thus preventing undesired magnetic agglomeration. To further 
assist in preventing agglomerations, to optimize bio-interactions with the host environment 
and to maximize biocompatibility, the choice of appropriate surface chemistries and 
functionalizations is also important. Different surface modifications have been reported to 
accommodate these characteristics in to the magnetic nanoparticles. These include tuning 
the particle size in the size range 3–30 nm with the particles displaying an ellipsoidal shape. 
A comprehensive characterization of such particles has been reported by Jolivet et al.  
USPIO enhanced magnetic resonance imaging (MRI) is now being used as a potential 
biomarker for the diagnosis of lymph node metastases. USPIOs are transported into the 
interstitial space and reach the SLN via the lymphatic circulation, acting as ‘negative 
imaging’ agents due to T2- and T2-weighted sequences, which can potentially identify the 
metastases independent of the lymph node size. However, reports also indicate that this 
predominant effect of USPIOs on the T2 relaxation time does not prevent the use of their 
properties for the T1 relaxation time when appropriate imaging sequences are chosen [150–
154]. USPIO nanoparticles are disseminated to the lymph nodes by two discrete pathways: 
a) USPIOs move into the medullary sinuses of the lymph node through venules via direct 
transcapillary passage, followed by phagocytosis by macrophages, b) USPIOs move into the 
interstitial space in the body through endothelial transcytosis, followed by uptake of the 
nanoparticles by draining lymphatic vessels and transport to the lymph nodes via afferent 
lymphatic channels. USPIOs with minor macrophage uptake and prolonged blood half-life 
have been shown to be useful for metastatic lymph node imaging. 
Various studies have shown that USPIO particles taken up by the macrophages are 
transported to the interstitial spaces and subsequently to the lymph node via the lymph 
vessels. Thus healthy lymph node tissues produce a dark signal with a T2/T2 sequence 
since they are rich in macrophages which phagocytose the USPIOs. However, no such 
contrast modification is observed in the metastatic lymph node tissue which lacks the 
presence of macrophages, thus facilitating the effective imaging of this tissue. Additionally, 
the prolonged blood half-life of USPIOs allows their progressive access to the lymph nodes 
thus helping in further enhancement of the quality of image which can be procured. 
Nodal disease is a self-determining adverse prognostic aspect in many types of cancers. By 
and far, measurement of the node size by means of imaging is the only widely established 
method for assessing this nodal involvement. In this regards, the superparamagnetic agents 
have raised immense attention because normal nodes posses high affinity towards these 
agents following intravenous or subcutaneous injection. The first agent, and also the most 
explored one is ferumoxtran-10. Numerous studies on ferumoxtran-10 have demonstrated 
its efficacy in metastatic lymph node imaging in various types of cancer with significant 
results being reported especially in case of breast cancer. 
Early results with ferumoxtran-10 MRI in breast cancer showed a sensitivity of 78%, a 
specificity of 96% and a negative predictive value of 97%. The SLN procedure in breast 
cancer has a 3%–10% false negative rate; furthermore, positive internal mammary lymph 
nodes are missed in 17%. Finally, the SLN is the only positive node in 61% lymph node 
positive patients. These patients all undergo axillary dissection, with subsequent high rate of 
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clinically significant lymph edema. The high negative predictive value in patients with a 
negative ferumoxtran-10 MRI thus exhibits a possibility that axillary dissection may 
potentially be avoided [163]. Further studies are required to confirm the potential use of 
these nanoparticles in SLN localization. 
Apart from the above discussed nanoparticulate systems, a variety of studies have been 
reported for SLN localization with various other types of magnetic nanoparticles. In one of 
the studies, SLN mapping of the stomach cancer has been reported using fluorescent 
magnetic nanoparticles (FMNP). Here the use of these nanoparticles was found to overcome 
problems such as unpredictable lymphatic drainage patterns and skipmetastases which are 
of common occurrences in these cancers and which limit the available imaging techniques 
for their precise diagnosis. Biocompatible silica-overcoated magnetic nanoparticles 
containing rhodamine B isothiocyanate (RITC) within a silica shell of controllable thickness 
of about 60 nm have also been used in some of the studies. 
In another study, Surguladze et al. have reported novel magnetic nanoparticles, UNIMAG, 
for SLN imaging. UNIMAG represents a magnet-sensitive stable suspension of magnetite 
nanoparticles (magnetic fluid). After the peritumoral injection of UNIMAG, the magnetite 
nanoparticles have been proposed to be absorbed by the macrophages,which deliver 
themthrough the lymphatic capillaries to regional lymph nodes. This mechanism of 
magnetite nanoparticle transport is responsible for the SLN detection. As compared to the 
other dyestuff agents used in this direction, magnetite nanoparticles were found to actively 
fill the lymphatic nodes and colored them in bold black. This significantly facilitated the 
atraumatic separation of the lymph nodes during lymphadenectomy. Besides the 
intraoperative indication of lymphatic nodes, UNIMAG also provided the possibility of X-
ray and ultrasound imaging of SLNs and the possibility of performing their biopsy in the 
preoperative period. Despite these promising results, there are several problems associated 
with the use of magnetic nanoparticles. These limitations include (i) the possibility of 
embolization of the blood vessels in the target region due to accumulation of the magnetic 
carriers, (ii) difficulties in scaling up from animal models due to the larger distances 
between the target site and the magnet, and (iii) toxic responses to the magnetic carriers. 
However, recent pre-clinical and experimental results indicate that there is still a possibility 
of overcoming these limitations and use the magnetic nanoparticles to provide enhanced 
imaging simultaneously handling the safety issues. 
4.5 Ultrasound nanobubbles 
Particulate agents are important for the regional lymph node contrast enhancement 
following their subcutaneous administration. 
These agents appear to traverse the endothelium of the peripheral lymphatics with 
subsequent localization in regional draining lymph nodes. Like other particulate 
nanocarriers, nanobubbles have been attempted for the ultrasound contrast enhancement of 
the regional lymph nodes. Nanobubble is a novel nanocarrier currently being widely 
investigated for the localization of the sentinel lymph node. 
Nanobubbles combine properties of polymeric drug carriers, ultrasound imaging imaging 
agents, and enhancers of ultrasound mediated drug delivery. In biological fluids and 
tissues, nanobubbles are efficient reflectors of sound. Ultrasound is the most common 
biomedical imaging modality and ultrasound imaging agents are used to increase the 
reflectivity or backscatter of blood and tissues. 
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Nanobubbles either comprise perfluorocarbon nanodroplets stabilized by walls made of 
biodegradable block copolymers or bilayered shell of albumin and an inner layer of a 
biodegradable polymer known as polycaprolactone. This shell encapsulates a gas such as 
nitrogen. Following their subcutaneous injection, these nanobubbles are tracked using 
ultrasound imaging. 
In a study carried out in dogs for comparing the activity of microbubbles with that of sub-
micron nanobubbles, the nanobubbles were found to bemore effective in detecting the 
sentinel nodes. In this study these nanobubbles were injected subcutaneously into normal 
dogs to target the cervical and popliteal lymph nodes. First-order (sentinel) lymph nodes 
and second-order sublumbar nodes were imaged intermittently from 0 h to at least 2 h 
following the contrast injection using continuous power Doppler mode. To confirm the 
lymphatic drainage patterns and sentinel lymph nodes of nanobubbles, lymphoscintigraphy 
studies were performed in dogs. Approximately 94% (30 of the 32) sentinel nodes were 
detected during this study. 
This nanobubble technology could serve as an alternative method for detecting the sentinel 
lymph node. This approach is also unique in that the use of ultrasound to detect the bubbles 
also causes the bubbles to break apart and formsmaller bubbles. It has been proposed that 
jets released from these nanobubbles following exposure to high-frequency ultrasound 
could be used to nanoinject drugs into cells. As these nanobubbles can also carry drugs, they 
could be used to deliver high levels of drugs to lymph nodes which could be rapidly 
released following insonation. However, concerns have been expressed that the energy 
released during this procedure lead to thermal tissue damage and thus harmful bioeffects 
and further investigations to verify these possible problems, are required in order to 
facilitate the introduction of a safe imaging modality. 
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